February 2012 Blog Posts (21)

Long-Term Cognitive Effects Study of Breast Cancer Chemotherapy Finds Subtle Impairment Among Women Who Received CMF Regimen

A summary of a study by Dutch investigators published online in the Journal of Clinical Oncology reported that women who received CMF chemotherapy, a combination regimen including the drugs Cyclophosphamide,…

Continue

Added by Peter Hofland, PhD on February 27, 2012 at 5:30pm — No Comments

New Hematopoietic Stem Cell Transplant Program Offers Treatment For Blood Cancers

The Virginia G. Piper Cancer Center at Scottsdale Healthcare has added a hematopoietic stem cell (HSC) transplant cancer treatment program through its new Cancer Transplant Institute.



The new cancer treatment program is expected to attract transplant patients from greater Phoenix, across Arizona and the southwestern United States. HSC transplants are primarily used to treat patients with aggressive…

Continue

Added by Peter Hofland, PhD on February 24, 2012 at 8:30am — No Comments

First Personalized Cancer Medicine Allows Patients with Deadly Form of Metastatic Melanoma to Live Significantly Longer

The European Commission has approved vemurafenib (ZelborafTM, Roche) as a monotherapy for the treatment of adult patients with BRAF V600 mutationpositive unresectable or metastatic melanoma. This form of melanoma is the most aggressive form of skin cancer. Vemurafenib is designed to target and inhibit mutated forms of the BRAF protein found in about half of all cases of melanoma.



When melanoma is…

Continue

Added by Peter Hofland, PhD on February 20, 2012 at 11:30am — No Comments

VAL-083 - Novel Treatment May Help Patients Suffering from GBM

The U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted orphan drug designation for VAL-083 for the treatment of glioma, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.



Of the estimated 17,000 primary brain tumors diagnosed in the United States each year, approximately 60% are gliomas. Attention was drawn to this form of brain cancer when Senator Ted Kennedy was…

Continue

Added by Peter Hofland, PhD on February 15, 2012 at 10:30pm — No Comments

Complexities of Non-Pharmacological Caregiving at the End of Life: "It's All About Satisfying Fundamental Human Needs"

Faced with the inevitability of death in late-stage palliative cancer care, relief of distress, optimized well-being and good caregiving during the final stage of life become primary treatment goals. A new study from Karolinska Institutet and Umeå University shows that non-pharmacological caregiving at the end of life in specialized palliative care is not as basic as one might…

Continue

Added by Peter Hofland, PhD on February 15, 2012 at 5:30pm — No Comments

Injectable Treatment for Blood Clots in Advanced Cancer Patients Increases

The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin (LMWH) to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist (February 14, 2012), funded by the National Cancer Institute and led by Kaiser Permanente…

Continue

Added by Peter Hofland, PhD on February 14, 2012 at 10:00am — No Comments

New Computer System Identifies Suitable Patients; Accelerate Cancer Trials - Helping New Drugs Reach Markets Faster

Moffitt Cancer Center & Research Institute (Tampa, Florida)  has received a new patent for a computerized system that efficiently selects the right patient for the right clinical trial. The newly patented system matches a registered patient's own molecular profile, warehoused in a database of thousands of patient-donated biological tissue or tumor samples, to the molecular design of the drug aimed at targeting their…

Continue

Added by Peter Hofland, PhD on February 14, 2012 at 8:30am — No Comments

Molecular Breast Imaging Superior to Ultrasound and Mammography for the Detection of Breast Cancer

According to a study published in the American Journal of Roentgenology (AJR) in January 2012, Molecular Breast Imaging (MBI), also known as Breast-Specific Gamma Imaging or BSGI, can detect cancers missed by the two most common breast imaging studies, mammography and ultrasound. To clearly differentiate between benign from malignant tissue after mammography, phycians perform BSGI/MBI. In this procedure a patient receives a…

Continue

Added by Peter Hofland, PhD on February 14, 2012 at 6:00am — No Comments

Prospective Analysis Links Breast and Pancreatic Cancer Risk With Lynch Syndrome

A new prospective study of patients with Lynch syndrome, an inherited disorder of cancer susceptibility caused by mutations in specific DNA repair genes, provides the first strong evidence that people with Lynch syndrome face significantly increased risks of breast and pancreatic cancers. The study also provided new, clearer estimates of the risks of cancers already recognized to be associated with Lynch syndrome, including those of the colon, uterus, ovary, kidney, stomach and…

Continue

Added by Peter Hofland, PhD on February 13, 2012 at 5:00pm — No Comments

Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models

Scientists at Roswell Park Cancer Institute have demonstrated that entinostat (Syndax Pharmaceuticals, Inc.), a class I benzamide histone deacetylase inhibitor also known as SNDX-275 and MS-275, has novel immunomodulatory properties that contribute to the enhanced activity of cancer immunotherapies in models of renal and prostate cancer.



Histone deacetylases (HDAC) are key enzymes that alter the…

Continue

Added by Peter Hofland, PhD on February 9, 2012 at 6:30am — No Comments

Early Detection Results in 15 Percent Drop in Prostate Cancer Deaths

While more men are being diagnosed with the prostate cancer, fewer are dying from the disease. Data from the North American Association of Central Cancer Registries and the National Center for Health Statistics, Centers for Disease Control and Prevention (CDC) show that in 2012, incidence rates of prostate cancer will increase slightly, while death rates from the disease will decrease. In 2011, 33,720 men died from the disease,…

Continue

Added by Peter Hofland, PhD on February 7, 2012 at 8:00am — No Comments

JX-594's Cancer Targeting Mechanism Driven by Genetic Traits Common in Solid Tumors

A new study published in Molecular Therapy shows that JX-594, a first-in-class targeted oncolytic virus products for cancer being developed by Jennerex, Inc selectively targets and kills a broad range of cancer cells.



The study demonstrated that JX-594's cancer-selectivity was multi-mechanistic and…

Continue

Added by Peter Hofland, PhD on February 7, 2012 at 5:30am — No Comments

DNA-targeting Molecule for Gene Correction, Gene Therapy and Gene Modification Show Promise as a Potential Therapy

Researchers at Fred Hutchinson Cancer Research Center have solved the three-dimensional structure of a newly discovered type of gene-targeting protein that has shown to be useful as a DNA-targeting molecule for gene correction, gene therapy and gene modification. The findings are published online in Science Expresson January 5,…

Continue

Added by Peter Hofland, PhD on February 5, 2012 at 4:30pm — No Comments

Dietary Soy Supplements do Not Provide Protection Against Breast Cancer - Effects of Food on Cancer May be More Complex

Soy isoflavone supplements did not decrease breast cancer cell proliferation in a randomized clinical trial, according to a study published in the February 2012 issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.



Lead researcher Seema A. Khan, M.D., professor of surgery at the…

Continue

Added by Peter Hofland, PhD on February 3, 2012 at 7:30pm — No Comments

New Targeted Drug Improves Overall Survival in Metastatic Prostate Cancer

A randomized phase III international trial presented at the fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, CA, USA, shows for the first time that an investigational oral drug that halts androgen signaling significantly improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC).…



Continue

Added by Peter Hofland, PhD on February 2, 2012 at 4:30pm — No Comments

Radium-223 Chloride Targeting Bone Metastases Improves Survival for Metastatic Castration-Resistant Prostate Cancer

A randomized, phase III, multi-national study, presented at fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, CA, USA, shows that a novel radiation-emitting agent that targets bone – and aimed at treating bone metastases – both improved survival and delayed cancer-related bone problems in men with metastatic castration-resistant prostate cancer (CRPC). The agent, radium-223 chloride or Ra-223…

Continue

Added by Peter Hofland, PhD on February 2, 2012 at 4:00pm — No Comments

External Beam Radiation (EBRT) Is Most Toxic and Expensive of the Three Common Prostate Cancer Treatments

An analysis of more than 100,000 prostate cancer patients, presented the fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, Ca, USA, shows that treatment with external beam radiation therapy (EBRT) resulted in higher long-term toxicities and treatment-related costs than prostatectomy and brachytherapy, two other common treatments for the disease. The results provide valuable insight that may…

Continue

Added by Peter Hofland, PhD on February 2, 2012 at 3:30pm — No Comments

Potential Role for Combination Drug Therapy to Battle Lung Cancer

Researchers at Translational Genomics Research Institute (TGen) and Van Andel Research Institute (VARI) today presented study results in which they conclude that a combination drug therapy may be needed to combat non-small cell lung cancer (NSCLC).



Non-small cell lung carcinoma (NSCLC) is characterized by a remarkable variety of genomic alterations and point…

Continue

Added by Peter Hofland, PhD on February 2, 2012 at 3:30pm — No Comments

Study Suggests IMRT Is Better Than Conventional Conformal Radiation Therapy (CRT) for Reducing Prostate Cancer Recurrence

A large comparative effectiveness study presented at the fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, Ca, USA, shows that men with localized prostate cancer who are treated with Intensity Modulated Radiation Therapy or IMRT are less likely to experience cancer recurrences or significant side effects from treatment than those who receive conventional conformal radiation therapy…

Continue

Added by Peter Hofland, PhD on February 2, 2012 at 3:00pm — No Comments

Vigorous Exercise May Guide Development of Strategies to Prevent or Delay Progression of Early-Stage Prostate Cancer

Men with early-stage prostate cancer who exercise vigorously at least three hours a week have more than 180 genes that are expressed differently in the prostate gland than those who did not exercise as intensively. These genes include known tumor suppressor genes and DNA repair pathways, suggesting that a better understanding of the molecular effects of exercise may guide development of strategies to prevent or delay cancer progression.



The results of the…

Continue

Added by Peter Hofland, PhD on February 2, 2012 at 2:00pm — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+